ABSTRACT
The draft genome sequences of two Nocardia farcinica strains isolated from two patients with cystic fibrosis (CF), resistant to trimethoprim/sulfamethoxazole and linezolid, are reported here. The estimated genome sizes were 5.8 Mb with a 70.63% G+C content. Transposases from Tn916 were detected, but not 23S rRNA mutation (G2576T) related to linezolid resistance.
GENOME ANNOUNCEMENT
Nocardia spp. are environmental bacteria that cause pulmonary infections similar to tuberculosis, and even disseminated disease (1, 2). Nocardia farcinica causes invasive infections with cerebral involvement (55%) and high mortality (35%) (1, 3). In Spain, resistance to trimethoprim/sulfamethoxazole (the cornerstone of treatment) in N. farcinica runs at 45% (4). Linezolid, with excellent bioavailability, provides an efficient alternative (1, 5). From childhood, patients with cystic fibrosis (CF) suffer frequent lung infections. From these patients, two N. farcinica strains (drug pattern type V [6]) highly resistant to trimethoprim/sulfamethoxazole and linezolid (MICs ≥32:608 and ≥256 µg/mL, respectively), were sequenced for a better understanding of their genetic background.
Paired-end libraries (Nextera-XT DNA library preparation kit, Illumina 1.9), were adapted and sequenced at 2 × 150 using Illumina NextSeq500. After quality control analysis involving fastQC v0.11.3 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and Trimmomatic v0.36 software (7), 3.1 million to 3.6 million paired-end reads of 50 to 151 bp were retrieved. Read assembly was performed using SPAdes v3.8.0 software (8) (kmer = 77), and the quality was evaluated using QUAST software (9).
The draft genomes of the strains, named CNM20080921 and CNM20091955, were both 5.8 Mbp long and had a G+C content of 70.63% (178 and 113 contigs of ≥500 bp; maximum, 674,734 and 1,141,487 bp; N50 value, 167,048 and 453,514 bp). Analysis using ANI software (10) revealed them to show 99.98% sequence similarity, and 99.28% similarity to N. farcinica NCTC11134 (GenBank accession number, NZ_LN868938). The assembled sequences were annotated using Prokka 1.12-beta software (11), which predicted 6,502 and 6,455 genes (6,428 and 6,381 protein-coding genes and 427 and 419 signal peptides, respectively), and 6 rRNAs, 67 tRNAs, and 1 transfer-messenger RNA (tmRNA) for both strains.
The following potential resistance genes (https://ardb.cbcb.umd.edu/, http://nocardia.nih.go.jp) were detected in both strains: bmr, stp, marR, mtdL, norM, emrB, emrY, FAR-1, ampC, aacA-aphD, aph(3′), ant1, neo, fstH, htpX, murA, ermH, tetA, tetC, tetR, mtdH, dfrA26, vanW, bac, qacA, sugE, acr3, ohrA, drrA, drrB, drrC, carA, merR, and yfmO; rmlA was detected in CNM20091955 only. Detected resistant genes by PCR sequencing of boiled extract of both strains (12), e.g., int1-3, sul1-2, ermTR, ermB, and tetO (and mefO for CNM20080921), were not detected by srst2 (13) and ARGANNOT (14) software (only int1, clmA, and FAR-1 were detected). Neither of the two 23S rRNA copies showed the G2576T mutation (Escherichia coli numbering) allowing linezolid resistance. However, one allele of CNM20080921 showed the change G2608A. Mobile element-related sequences, such as IS5376/IS6110, tnpR (resolvase) guaA (integration hot spot), three IS3-family transposases, and two transposases from Tn916, were identified in both strains.
Similar virulence contents were detected such as mammalian cell entry protein, ESX-1, and others (fbpA, fbpB, fbpC, sodC, katA, katE, katG, ideR, nbtB, nbtD, nbtE, nbtF, nbtG, nbtS, aphC, aphD, narG, oxyR, ndk, ptpA, tlyA, and tlyC) (15). The biosynthetic gene clusters for CNM20080921 and CNM20091955 were 7 and 9 nonribosomal peptide synthases, 4 and 5 polyketide synthases, 5 terpene cyclases, and ectoine and nocobactin genes, respectively (16). Clustered regularly interspaced short palindromic repeats (CRISPR) (12 and 11, respectively) were found in each one. In both strains, the same incomplete prophage (7.4 Kb, 71.39% G+C) was identified (17).
Given their exposure to viral/bacterial infections and frequent antimicrobial treatment, the pulmonary microbiomes of patients with CF are fragile. If lung transplantation is to be successful in such patients, the surveillance of Nocardia species is needed (see reference 18).
Accession number(s).
This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession numbers NXEH00000000 and NXEG00000000 for CNM20080921 and CNM20091955, respectively. The versions described in this paper are versions NXEH01000000 and NXEG01000000.
ACKNOWLEDGMENTS
We are grateful to G. Carrasco, P. Jimenez, and J. A. Saéz-Nieto for their help in different stages of genome sequencing, and Adrian Burton for editing and language assistance (Physical Evidence Scientific Translations; http://www.physicalevidence.es).
This work was funded by project MPY1278/15 of the Instituto de Salud Carlos III.
Footnotes
Citation Valdezate S, Monzón S, Garrido N, Zaballos A, Medina-Pascual MJ, Azcona-Gutiérrez JM, Vilar B, Cuesta I. 2017. First insight into the genome sequences of two linezolid-resistant Nocardia farcinica strains isolated from patients with cystic fibrosis. Genome Announc 5:e01212-17. https://doi.org/10.1128/genomeA.01212-17.
REFERENCES
- 1.Tremblay J, Thibert L, Alarie I, Valiquette L, Pépin J. 2011. Nocardiosis in Quebec, Canada, 1988–2008. Clin Microbiol Infect 17:690–696. doi: 10.1111/j.1469-0691.2010.03306.x. [DOI] [PubMed] [Google Scholar]
- 2.Ambrosioni J, Lew D, Garbino J. 2010. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 38:89–97. doi: 10.1007/s15010-009-9193-9. [DOI] [PubMed] [Google Scholar]
- 3.Al-Tawfiq JA, Al-Khatti AA. 2010. Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis. Int J Infect Dis 14:e153–e157. doi: 10.1016/j.ijid.2009.03.017. [DOI] [PubMed] [Google Scholar]
- 4.Valdezate S, Garrido N, Carrasco G, Medina-Pascual MJ, Villalón P, Navarro AM, Saéz-Nieto JA. 2017. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother 72:754–761. doi: 10.1093/jac/dkw489. [DOI] [PubMed] [Google Scholar]
- 5.Rivero A, García-Lázaro M, Pérez-Camacho I, Natera C, Almodovar MC, Camacho A, Torre-Cisneros J. 2008. Successful long-term treatment with linezolid for disseminated infection with multiresistant Nocardia farcinica. Infection 36:389–391. doi: 10.1007/s15010-008-7236-7. [DOI] [PubMed] [Google Scholar]
- 6.Clinical & Laboratory Standards Institute 2011. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes, 2nd ed, vol. 31, no. 5. Approved standard M24-MA2 National Committee for Clinical Laboratory Standards, Wayne, PA. [PubMed] [Google Scholar]
- 7.Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120. doi: 10.1093/bioinformatics/btu170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. doi: 10.1089/cmb.2012.0021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gurevich A, Saveliev V, Vyahhi N, Tesler G. 2013. QUAST: quality assessment tool for genome assemblies. Bioinformatics 29:1072–1075. doi: 10.1093/bioinformatics/btt086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Zhang W, Du P, Zheng H, Yu W, Wan L, Chen C. 2014. Whole-genome sequence comparison as a method for improving bacterial species definition. J Gen Appl Microbiol 60:75–78. doi: 10.2323/jgam.60.75. [DOI] [PubMed] [Google Scholar]
- 11.Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068–2069. doi: 10.1093/bioinformatics/btu153. [DOI] [PubMed] [Google Scholar]
- 12.Valdezate S, Garrido N, Carrasco G, Villalón P, Medina-Pascual MJ, Saéz-Nieto JA. 2015. Resistance gene pool to co-trimoxazole in non-susceptible Nocardia strains. Front Microbiol 6:376. doi: 10.3389/fmicb.2015.00376. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, Zolber J, Holt KE. 2014. SRST2: Rapid genomic surveillance for public health and hospital microbiology labs. Genome Med 6:90. doi: 10.1186/s13073-014-0090-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, Rolain JM. 2014. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. Antimicrob Agents Chemother 58:212–220. doi: 10.1128/AAC.01310-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Ishikawa J, Yamashita A, Mikami Y, Hoshino Y, Kurita H, Hotta K, Shiba T, Hattori M. 2004. The complete genomic sequence of Nocardia farcinica IFM 10152. Proc Natl Acad Sci U S A 101:14925–14930. doi: 10.1073/pnas.0406410101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Blin K, Medema MH, Kottmann R, Lee SY, Weber T. 2017. The antiSMASH database, a comprehensive database of microbial secondary metabolite biosynthetic gene clusters. Nucleic Acids Res 45:D555–D559. doi: 10.1093/nar/gkw960. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. 2011. PHAST: A fast phage search tool. Nucleic Acids Res 39:W347–W352. doi: 10.1093/nar/gkr485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Chacón CF, Vicente R, Ramos F, Porta J, Lopez Maldonado A, Ansotegui E. 2015. Nocardia farcinica lung infection in a patient with cystic fibrosis and a lung transplant. Rev Esp Anestesiol Reanim 62:161–164. doi: 10.1016/j.redar.2014.04.010. [DOI] [PubMed] [Google Scholar]